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OligonucleotideSpinal muscular atrophy (SMA) is a neuromuscular disease caused by disruption of the survival motor neuron 1
(SMN1) gene, partly compensated for by the paralogous gene SMN2. Exon 7 inclusion is critical for full-length
SMN protein production and occurs at a much lower frequency for SMN2 than for SMN1. Antisense oligonucleotide
(ASO)-mediated blockade of an intron 7 splicing silencer was previously shown to promote inclusion of SMN2 exon
7 in SMA mouse models and mediate phenotypic rescue. However, downstream molecular consequences of this
ASO therapy have not been deﬁned. Here we characterize the gene-expression changes that occur in an induced
model of SMA and show substantial rescue of those changes in central nervous system tissue upon intracerebroven-
tricular administration of an ASO that promotes inclusion of exon 7, with earlier administration promoting greater
rescue. This study offers a robust reference set of preclinical pharmacodynamic gene expression effects for compar-
ison of other investigational therapies for SMA.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive neuromus-
cular disorder in which progressive α-motor neuron degeneration leads
to weakness and atrophy of primarily proximal skeletal muscles [1]. The
underlying genetic defect is the loss of function, usually deletion, of
survival motor neuron 1 (SMN1) [2], which encodes the protein SMN in-
volved in the assembly of small nuclear ribonucleoprotein complexes
[3]. A neighboring gene centromeric to SMN1 at chromosome 5q13,
SMN2, arose from duplication and subsequent mutation of SMN1 and is
unique to humans [4]. The handful of nucleotide differences between
SMN1 and SMN2 include a CNT transition in SMN2 at position 6 of exon, cyclin-dependentkinase inhib-
ry rate; FUS, fused in sarcoma;
ar; ISS, intronic splicingsilencer;
BS, phosphate-buffered saline;
erase chain reaction; RT, reverse
motorneuron;snRNP,smallnu-
lli).
. This is an open access article under7. Together with an intronic splicing silencer (ISS) in intron 7, termed
ISS-N1 [5], this nucleotide difference suppresses inclusion of exon 7,
thereby encoding a truncatedprotein product, SMNΔ7,which is essential-
ly non-functional and rapidly degraded. However, at some frequency,
SMN2 does generate transcripts that include exon 7 and encode a full-
length SMN protein identical to that encoded by SMN1.
SMN2 is itself subject to gene duplication, and its copy number is the
major genetic modiﬁer of SMA phenotype from type I (severe with in-
fantile onset) to type IV (mild with adult onset). This pattern is recapit-
ulated inmurinemodels of SMA inwhich knockout of the singlemurine
Smn gene, which results in embryonic lethality [6], can be rescued by a
variable copy number of the human SMN2 transgene. Smn knockout
mice with two copies of SMN2 (Smn–/–; SMN2+/0) model a severe
form of SMA, with mice surviving ~1 week [7,8]. A strain with an addi-
tional human SMN2 complementary DNA (cDNA) transgene lacking
exon 7 (Smn–/–; SMN2+/0; SMNΔ7) lives to ~15 days [9]. Mice with
four copies of the SMN2 transgene (Smn–/–; SMN2+/+) model a very
mild form of SMA and have a normal lifespan, but develop ear and tail
necrosis likely secondary to vascular deﬁcits [7].
The partly compensatory activity of SMN2 has made it an attractive
target for molecules that promote inclusion of exon 7 and therefore in-
crease the level of functional SMN protein in the setting of SMN1the CC BY license (http://creativecommons.org/licenses/by/4.0/).
221J.F. Staropoli et al. / Genomics 105 (2015) 220–228deﬁciency. Indeed, a 2′-O-(2-methoxyethyl)-modiﬁed antisense oligonu-
cleotide (ASO), designated ASO 10-27, targets a site within intron 7 that
overlaps with ISS-N1 and promotes efﬁcient inclusion of SMN2 exon 7.
ASO 10-27, which mediates partial phenotypic rescue of both severe
andmildmodels of SMA [10,11], also is known as ISIS-SMNRx, a drug cur-
rently undergoing investigation in children and infants with SMA.
In evaluating the pharmacodynamic proﬁle and therapeutic efﬁcacy
of candidate compounds, a model with an intermediate phenotype is of
particular value. Therefore, an inducedmodel of SMAwas developed by
administering adultmicewithmild SMAanASO, designated ASO 20-37,
that targets a purine-rich exon splicing enhancer region in themiddle of
exon 7 and promotes skipping of SMN2 exon 7 beyond background
levels of exon 7 exclusion [12,13].We recently described the phenotypic
and histopathologic effects of induced SMN depletion and repletion
with ASO 20-37 (skip) and ASO 10-27 (therapeutic), respectively, deliv-
ered by intracerebroventricular (ICV) injection in neonatal [12] and
adult [13] mice with SMA. The consequences of SMN2 mis-splicing
were progressive and dose dependent. For instance, in 2-month-old
mice administered the skip ASO 20-37, effects on bodyweight and loco-
motor activity were apparent by day 30 after injection of the 100-μg
dose, but not until after day 60 at the 25-μg dose. SMA-like pathology
appeared in parallel and included reduced α-motor neuron density,
neuromuscular junction defects, decreased muscle ﬁber sizes and re-
duced numbers of central synapses onto motor neurons. Early ICV, but
not intraperitoneal, administration of the therapeutic ASO 10-27 at 5
or 22 days after ICV delivery of the skip ASO 20-37 signiﬁcantly
prolonged survival and reversed the subset of abnormal phenotypes
analyzed.
In this report, we describe the gene-expression signature of the fore-
going induction and rescue paradigm. Previous expression proﬁling of a
severe model [14] was likely confounded by marked developmental
changes that normally occur in the spinal cord of neonatal mice [15].
Moreover, expression changes secondary to profound tissue damage in
models of severe SMA may mask dysregulation that is a direct conse-
quence of SMN loss of function, although a recent study attempted to cir-
cumvent these potential effects by analyzing overtly pre-symptomatic
post-natal day 1 (P1) mice [16]. We show that induction of SMA in
adult mice did not yield signiﬁcant gene-level expression changes until
30 days post-induction and that many of these changes could be
prevented or reversed by administration of an ASO that promotes exon
7 inclusion, with earlier treatment improving survival and degree of tran-
scriptional rescue. These data provide an important catalog of pharmaco-
dynamic biomarkers of SMN depletion and restoration that can guide
preclinical evaluation of novel SMA therapeutics. In addition, this analysis
highlights molecular pathways proximal to SMN function, including cell-
cycle signaling, forwhich recent evidence has emerged from independent
analyses of SMN protein function and models of SMA.
2. Results
2.1. Physiologic early post-natal gene-expression changes in the mouse
spinal cord far exceed genotype-driven changes in a model of severe SMA
We ﬁrst sought to evaluate whether a well-characterized model of
severe SMA could serve as a tool for pharmacodynamic monitoring on
the basis of gene-expression. We used 3′ microarrays to assess gene-
level expression in spinal cord tissue from mice with severe SMA
(Smn–/–; SMN2+/0) [17,18]. Because these mice survive only ~10 days,
analysis was necessarily limited to the early post-natal period; tissue
was analyzed fromﬁvemice each at P1 and P5. Littermates heterozygous
for endogenous Smn and carrying four copies of the human transgene
(Smn+/–; SMN2+/+) [7] served as the comparator group (n = 5 for
each time point). The vast majority of changes were driven by develop-
mental stage (P1 versus P5) rather than by genotype (control versus
SMA; Fig. 1 and Supplemental dataset S1), consistentwith previous ﬁnd-
ings in the Smn–/–; SMN2+/0; SMNΔ7models at P1, P7 and P13 [15]. Infact, changes in the control group between P1 and P5 were even greater
than those in the SMA group during the same period, suggesting that the
developing spinal cord undergoes signiﬁcant physiologic changes in the
early post-natal period. Of note, among the few genotype-driven chang-
es at P5, up-regulation of the transcripts for cyclin-dependent kinase in-
hibitor 1A (Cdkn1a; p21) and histone cluster 1, H1c (Hist1H1C) also had
been reported as genotype-driven changes at P7 in the Smn–/–, SMN2+/0,
SMNΔ7model [15].2.2. Induction of SMA in adult mice causes a delayed and coordinated
transcriptional response
Given that (1) few genotype-driven changes were present in a
model of severe SMA and (2) signiﬁcant early post-natal expression
changes in the mouse spinal cord would likely confound any changes
mediated by ASO therapy, we decided to analyze gene-expression
changes in a more recently characterized induced model of SMA [12,
13]. To evaluate the time course of transcriptional changes induced by
skipping SMN2 exon 7 beyond background levels of exon 7 exclusion,
15-week-old mice with mild SMA (Smn–/–; SMN2+/+) [7] were given
a single ICV bolus injection of 50 μg exon 7 skip ASO 20-37 or a control
ASO, and central nervous system tissue (spinal cord and brain) was col-
lected 10, 20 or 30 days after treatment (Table 1). Median survival at
this dose and age of administration was 37 days with the skip ASO
(Fig. 2A), falling between the median survival of 70 and 34 days at the
25-μg and 100-μg doses, respectively, as reported in our previous
study [13]. Reverse transcription (RT) polymerase chain reaction
(PCR) for the SMN2 transgene from the lumbar cord (Fig. 2B) and
brain (Supplemental Fig. S1) showed that the skip ASO induced a pro-
gressive suppression of exon 7 inclusion between days 10 and 30 post
injection. The control ASO had a minimal effect on SMN2 splicing
over the same interval in the lumbar cord and brain (Fig. 2B and
Supplemental Fig. S1).
To identify global expression changes induced by acute SMN deple-
tion, the cervical portions of the spinal cords from the above mice were
used to analyze gene-level changes using 3′ arrays as well as exon-level
changes using a microarray with 750,000 probes covering 250,000
exons. Unsupervised hierarchical clustering analysis of gene-level ex-
pression changes post injection showed stable expression patterns at
days 10 and 20 post injection, but marked changes at day 30 across
the cohort receiving the skip ASO (Figs. 2C and D and Supplemental
Dataset S2). The only statistically signiﬁcant gene-level changes that o-
verlapped with genotype-driven changes in the severe model assessed
above were up-regulation of the transcripts for Cdkn1a (p21) and
Hist1H1C and down-regulation of the transcript for albumin D-box
binding protein (Adbp). Two of these changes (up-regulation of
Cdkn1a and Hist1H1C) overlapped with the set of genotype-driven
changes observed at day 7 in the Smn–/–; SMN+/–; SMNΔ7models [15],
suggesting that these are molecular signals closely linked to SMN func-
tion, robust across severalmodels of SMA and independent laboratories.
A more recent study using RNA-Seq of laser-capture-microdissected
motor neurons from Smn–/–; SMN+/–; SMNΔ7mice at post-natal day 1
also showed signiﬁcant upregulation of Cdkn1a [16]. Eleven other up-
regulated transcripts were shared between these datasets (Supplemen-
tal Fig. S2) and included components of the C1q complex, whose
upregulation is hypothesized to promote overpruning of synapses in
the severe model of SMA [16]. Pathway analysis of altered transcripts
in the current study showed a signiﬁcant enrichment of gene ontology
terms for the complement system, cell cycle signaling and apoptosis
signaling (Table 2).
Statistically signiﬁcant exon-level changes were relatively few and,
as with the gene-level changes, appeared primarily at day 30 post-in-
duction (Supplemental Table S1). A subset of exons whose expression
was altered relative to constitutively expressed exons from the same
gene was analyzed on a microﬂuidic quantitative PCR (qPCR) platform
Fig. 1. (A) Gene-level expression changes in spinal cord tissue of an uninducedmodel of severe SMA (Smn–/–; SMN2+/0) versus control littermates (Smn+/–; SMN2+/+) at P1 and P5; n=5
for each group. Fold changes≥1.5 with an FDR-adjusted P-value b 0.05 are shown. (B) Venn diagram showing relationship between gene-expression changes presented in (A). The small
number of changes in the P1 SMA versus P1 control comparison is omitted for clarity. FDR, false discovery rate; P, post-natal day; SMA, spinal muscular atrophy; SMN, survival motor
neuron.
222 J.F. Staropoli et al. / Genomics 105 (2015) 220–228(Fluidigm Corporation), and the results were consistent with those ob-
tained by microarray (Supplemental dataset S3 and text ﬁle S1).
2.3. Induced transcriptional changes can be prevented or reversed in a
time-dependent manner with an ASO-promoting inclusion of SMN2 exon 7
Given that most transcriptional changes occurred 30 days post-
induction, we sought to determine whether those changes could be
prevented before that point or reversed at that point by administra-
tion of a 20-mer ASO that, similar to ISIS-SMNRx, blocks the intron 7
splicing silencer ISS-N1 and enhances inclusion of SMN2 exon 7.
Eight-week-old mice were treated with the skip or control ASO,
and then with the therapeutic ASO on day 20, 25 or 30 after disease
induction. The complete list of treatments is given in Table 3.
As in the 15-week-old cohort used in the ﬁrst induction experiment,
median survival was 37 days post-induction with no further treatment.
When administered on day 20, the therapeutic ASO prevented death of
all sixmice in the cohort until at least day 54, but rescuewas incomplete
when administration of the therapeutic ASO was delayed to day 25 or
30 post-induction (Fig. 3A). The therapeutic ASO promoted inclusion
of exon 7 in the SMN2 transcript (Fig. 3B) and increased SMN protein
levels as assessed by immunoblotting of spinal cord whole cell lysates
(Fig. 3C) and immunohistochemistry of thoracic spinal cord sections
(Fig. 3D). Mice injected with the skip or control ASO (groups D and E;
Table 3) were sacriﬁced 30 days later and their spinal cords were re-
moved for gene-expression proﬁling performed as described above to
assess the reproducibility of day 30 expression changes obtained in
the ﬁrst induction experiment. The mice that received the therapeutic
ASO on day 20, 25 or 30 post-induction and survived to day 54 (six of
six, ﬁve of six, and three of six animals, respectively) were sacriﬁced at
that point and analyzed similarly.
A total of 363 transcripts changed by ≥1.5-fold with the skip ASO
versus control ASO treatment at day 30 (group D versus E; Table 3 and
Supplemental dataset S4). Of these, 132 transcripts changed by ≥2-Table 1
SMA induction experiment.
Group no. Injection D0 Day of sacriﬁce No. of mice
A PBS 10 5
B Control ASO, 50 μg 10 5
C Control ASO, 50 μg 20 5
D Control ASO, 50 μg 30 5
E Skip ASO, 50 μg 10 5
F Skip ASO, 50 μg 20 5
G Skip ASO, 50 μg 30 7
ASO, antisense oligonucleotide; D, day; PBS, phosphate-buffered saline; SMA, spinal mus-
cular atrophy.fold and these changes overlapped substantially with those in the ﬁrst
induction experiment in 15-week-old mice (Fig. 4A; hypergeometric
P-value = 6.8 × 10−144), supporting the robustness of our analysis.
The second cohort (8 weeks old) was 7 weeks younger than the ﬁrst
cohort; therefore, the consistency of the data also suggested that most
transcriptional changes indeed arose from induced SMN depletion,
rather than physiologic post-developmental changes during this period
of adulthood.
Administration of the therapeutic ASO at day 20 post-induction
(group I; Table 3) prevented 248 of 363 (68%) transcripts from changing
by N50% of their baseline (control ASO treated) levels at the time of
analysis (day 54 post-induction; Figs. 4B and C and Supplemental
dataset S4). The percentage of rescued transcripts at this same time
point fell to 47% when administration of the therapeutic ASO was de-
layed to day 25 post-induction (group J); these transcripts were a com-
plete subset of those rescued in group I. By day 30 post-induction,when
most of the skip ASO-induced changes had set in, the therapeutic ASO
restored 31% of altered transcripts to N50% of their baseline levels
(group K); these were a complete subset of those rescued in group J,
with the exception of one transcript (Agxt2l1), which appeared among
the rescued transcripts in groups I and K but not those in group J. An ex-
ample of a transcript for which the therapeutic ASO both prevented and
reversed changes induced by the skip ASO is Gdf15 (Fig. 4D, left panel).
Tgfbi is an example of a transcript for which the change was prevented
by the therapeutic ASO at day 20 or 25 post-induction, but not reversed
when administration was delayed to day 30 post-induction (Fig. 4D,
right panel). Pathway analysis of rescued transcripts revealed that cell
cycle signaling was the most signiﬁcantly represented pathway both
among transcripts prevented from changing by therapeutic ASO admin-
istration at day 20 or 25 (Table 4) and among transcripts that had al-
ready changed and were reversed by therapeutic ASO administration
at day 30 (Table 5).
Selected transcripts with statistically signiﬁcant changes were ana-
lyzed on a microﬂuidic qPCR platform (Fluidigm Corporation), and fold
changes were consistent with the microarray results (Supplemental
dataset S5 and text ﬁle S2). Given recent reports of a functional associa-
tion between SMN and genes implicated in amyotrophic lateral sclerosis
[19,20], we also analyzed expression of the transcripts for fused in sarco-
ma (Fus), TAR DNA-binding protein (Tardbp) and valosin-containing
protein (Vcp) in this analysis and conﬁrmed the lack of signiﬁcant ex-
pression changes observed by microarray (Supplemental dataset S5).
Selected transcripts that were signiﬁcantly altered at day 30 post-
induction, including Sgca, Eda2r, Igfbp2, Cdkn1a, Tgfbi, and Iﬁ44, were
mostly unchanged at the protein level, as assessed by immunoblotting
of corresponding spinal cord lysates (Supplemental Fig. S3 and data
not shown). Of this group, only Igfbp2 was signiﬁcantly changed
(~1.7-fold increase in skip versus therapeutic ASO-treated mice). This
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Fig. 2. (A) Kaplan–Meier survival curve of 15-week-oldmicewithmild SMA (Smn–/–; SMN2+/+; n=12) given an ICV bolus injection of 50 μg skip ASO 20-37. (B) RT-PCR quantiﬁcation of
exon 7 inclusion or exclusion in the spinal cord as a fraction of total SMN2 transcript for each of the cohorts described in Table 1. Datawere normalized to the PBS-treated cohort (groupA).
(C) Unsupervised hierarchical clustering analysis of gene-level expression changes for the cohorts described in Table 1. Letters on the horizontal axis correspond to individual animals in
each of the designated cohorts. The heat map shows a Z-score transformation of probe intensity values compared to the population mean. (D) Quantiﬁcation of gene-expression changes
induced by skip oligo at D10, D20 and D30 post induction in spinal cord tissue with≥2-fold change and FDR b0.05. ASO, antisense oligonucleotide; D, day; FDR, false discovery rate; ICV,
intracerebroventricular; PBS, phosphate-buffered saline; RT-PCR, reverse transcription polymerase chain reaction; SMA, spinal muscular atrophy; SMN, survival motor neuron.
Table 2
Pathway analysis of gene-expression changes induced by skip oligo at D30.
Ingenuity canonical pathways − log(P)
Complement system 5.15
Cell cycle signaling 5.09
Apoptosis signaling 5.03
Fcγ receptor-mediated phagocytosis 4.82
Acute phase response signaling 4.46
Tissue remodeling 4.41
Dendritic cell maturation 4.34
NK cell signaling 3.02
Death receptor signaling 2.81
Crosstalk between dendritic and NK cells 2.79
Pathway analysis of gene-expression changes induced by skip oligo at D30.
Top canonical pathways and Fisher's exact test-derived P-values for enrich-
ment are shown.
D, day; NK, natural killer.
223J.F. Staropoli et al. / Genomics 105 (2015) 220–228discordance between gene expression andprotein changes has beenob-
served in other models of SMN [21]. Notably, although gemin 2 and
gemin 8 were not altered at the level of gene expression, the protein
levels of both signiﬁcantly increased with therapeutic ASO treatment,
consistent with the observation that SMN stabilizes gemin proteins [3].3. Discussion
In this study, we set out to characterize transcriptional changesmost
proximal to SMN function that therefore represent candidate bio-
markers for therapeutic engagement by an ASO that increases levels of
full-length SMN by promoting inclusion of exon 7 in the SMN2 tran-
script. Selecting the proper model for this analysis among the many
that have been characterized is of critical importance. Murine models
of severe SMA highlight the critical role of SMN in early pre- and post-
synaptic development of the neuromuscular junction [7,9,11], but the
Table 3
Treatment plan to evaluate prevention/reversal of induced transcriptional changes.
Group no. Injection D0 Injection D20 Day of sacriﬁce No. of mice
A PBS None 20 4
B Skip ASO, 50 μg None 20 4
C Control ASO, 50 μg None 20 4
D Skip ASO, 50 μg None 30 5
E Control ASO, 50 μg None 30 5
F Skip ASO, 50 μg Therapeutic ASO, 100 μg 40 6
G Control ASO, 50 μg Therapeutic ASO, 100 μg 40 6
H Skip ASO, 50 μg None Survival curve 6
I Skip ASO, 50 μg Therapeutic ASO at D20, 100 μg 54 6a
J Skip ASO, 50 μg Therapeutic ASO at D25, 100 μg 54 6b
K Skip ASO, 50 μg Therapeutic ASO at D30, 100 μg 54 6c
ASO, antisense oligonucleotide; D, day; PBS, phosphate-buffered saline.
a All six mice survived at D54.
b Five of six mice survived at D54.
c Three of six mice survived at D54.
224 J.F. Staropoli et al. / Genomics 105 (2015) 220–228concomitant profound effect on overall post-natal development and
survival makes it difﬁcult to separate transcriptional responses primary
to SMN function from those secondary to degenerative changes. More-
over, signiﬁcant changes in the spinal cord transcriptome are associated
with normal development in the early post-natal period [15]. Our own
analysis reproduced the ﬁnding that transcriptional changes in theFig. 3. (A) Kaplan–Meier survival curves for 8-week-oldmicewithmild SMA treated as describe
for further analysis. (B) RT-PCRquantiﬁcation of exon 7 inclusion or exclusion in the spinal cord
normalized to the PBS-treated cohort (group A). (C) Immunoblotting of whole cell spinal cord
probed ﬁrst for SMN and then re-probed for α-tubulin. (D) Representative anti-SMN immuno
antisense oligonucleotide; D, day; ICV, intracerebroventricular; PBS, phosphate-buffered saline
SMN, survival motor neuron.spinal cord in the ﬁrst post-natal week far outnumber any genotype-
driven changes during the same period. We therefore used an induced
adult model of SMA to minimize the confounding effects of early post-
natal development on the transcriptional signature of SMN deﬁciency.
The current study showed that the extent of molecular rescue was
time dependent, with earlier administration of the therapeutic ASOd in Table 3. Curves are presented for groups H–K. Allmice surviving to D54were sacriﬁced
as a fraction of total SMN2 transcript for each of the cohorts described in Table 3. Datawere
lysates prepared from individual animals in the indicated treatment groups. The blot was
histochemistry of thoracic spinal cord sections from the indicated treatment groups. ASO,
; RT-PCR, reverse transcription polymerase chain reaction; SMA, spinal muscular atrophy;
Fig. 4. (A) Overlap of gene-level expression changes (≥2-fold; FDR b0.05) induced by ASO 20-37 at D30 in the ﬁrst cohort (group G versus group D; Table 1) versus the second cohort
(group D versus group E; Table 3). The probability that this subset of genes overlapped by chance, P= 6.82 × 10–144, is based on the hypergeometric distribution and the observation
that ≥15 000 unique genes were detectable in mouse spinal cord by the microarray platform used in this study. (B) Rescued transcripts are deﬁned as those whose expression levels
are restored to≥50% of their baseline (control ASO treated) levels. (C) Number of DEGs induced byASO 20-37 at D30 (363 total DEGswith≥1.5-fold changes; FDR b0.05) that are rescued
in the indicated treatment group (groups I, J and K; Table 3). Median percentage reversal indicates the median degree of reversal to baseline expression across all 363 DEGs. The Venn
diagram shows the relationship between rescued transcripts for groups I, J and K. (D) (Left) Rescue of Gdf15 expression level with therapeutic ASO at D20 (group I), D25 (group J) and
D30 (groupK)post induction. (Right) Rescue of Tgfbi expression levelwith therapeutic ASO atD20 (group I) andD25 (group J) but not atD30 (groupK)post induction. Each dot represents
data from an individual animal, and box-and-whisker plots showmedian, ﬁrst and third quartiles and outlier-excluded ranges for expression data in a given treatment group. ASO, anti-
sense oligonucleotide; D, day; DEG, differentially expressed gene; FDR, false discovery rate.
225J.F. Staropoli et al. / Genomics 105 (2015) 220–228(i.e. day 20 post-induction) showing better resolution of the expression
proﬁle than later administration (i.e. day 25 or 30 post-induction). Con-
sistent with a previous report that exon-level changes are a late occur-
rence in SMN-deﬁcient mice and more likely reﬂect secondary rather
than primary effects of SMN deﬁciency on splicing [15], we identiﬁed
few differential splicing signals upon ASO-induced SMN depletion.
This reproducible ﬁnding was somewhat surprising, given the deﬁned
role of SMN in spliceosomal small nuclear ribonucleoprotein (snRNP)
biogenesis [3,14], suggesting that splicing is relatively robust to the al-
tered snRNP repertoire in the setting of SMN deﬁciency and raising
the possibility of an incompletely elucidated compensatory pathway.
Of note, a recent RNA-Seq analysis of laser capture-microdissected
motor neurons from P1 Smn–/–; SMN2+/0; SMNΔ7mice revealed ~100
splicing aberrations, mostly in genes whose overall expression wasunchanged [16]. This remains a small number of splicing changes
given the purported centrality of SMN in snRNP biogenesis.
In the current study, SMN depletion had a far greater effect on gene-
level expression than on detectable splicing events. Interestingly, gene
ontology pathway analysis of transcripts most robustly rescued by the
therapeutic ASO revealed that cell cycle signaling pathways were the
most signiﬁcantly represented. This ﬁnding is consistent with indepen-
dent lines of evidence that have demonstrated an impact of SMNdeﬁcien-
cy on DNA replication and possibly DNA repair, and have suggested that
SMA is not only a degenerative disorder, but also a neurodevelopmental
disorder. DevelopingDrosophila larvae showed a temporospatial gradient
of Smn protein, with levels in the central nervous system highest in pro-
liferative post-embryonic neuroblasts [22]. Loss or gain of Smn function
disrupts larval growth and germline stem cell proliferation and
Table 4
Top gene pathways prevented from changing in the induced model by ad-
ministration of the therapeutic ASO.
Ingenuity canonical pathways − log(P)
Cell cycle signaling 8.89
Aryl hydrocarbon receptor signaling 5.22
Tec kinase signaling 2.97
Role of pattern recognition receptors 2.88
Cholecystokinin/gastrin-mediated signaling 2.80
Granulocyte adhesion and diapedesis 2.76
NRF2-mediated oxidative stress response 2.70
Agranulocyte adhesion and diapedesis 2.65
IL-8 signaling 2.63
PI3K/AKT signaling 2.49
Cell cycle: G1/S checkpoint regulation 2.37
IL-10 signaling 2.33
CCR5 signaling in macrophages 2.30
Glioblastoma multiforme signaling 2.21
Estrogen-mediated S-phase entry 2.21
VDR/RXR activation 2.17
Altered T cell and B cell signaling 2.05
Acute phase response signaling 2.00
Complement system 1.94
Glioma signaling 1.93
Oncostatin M signaling 1.91
IGF-1 signaling 1.91
Cell cycle regulation by BTG family proteins 1.89
IL-17A signaling in ﬁbroblasts 1.89
HGF signaling 1.87
ASO, antisense oligonucleotide; CCR5, C-C chemokine receptor type 5; HGF,
hepatocyte growth factor; IGF, insulin-like growth factor; IL, interleukin;
VDR, vitamin D receptor; RXR, retinoid X receptor.
226 J.F. Staropoli et al. / Genomics 105 (2015) 220–228differentiation. Furthermore, amousemodel of severe SMA showed a sig-
niﬁcant reduction in brainweight and cell number, particularly in the hip-
pocampus, secondary to reduced proliferative capacity, not increased
apoptotic cell death [23].
These ﬁndings were not so surprising, given that nuclear Cajal bod-
ies, spliceosome biogenesis factories of which SMN is a component,
may have a role in the G1/S phase transition in proliferating Schwann
cells [24]. SMN co-localizes with cyclin-dependent kinase 2 during this
transition and also promotes assembly of the U7 snRNP, required for
histone mRNA 3′ end processing [25]. Together, these ﬁndings suggest
that SMN contributes to the coupling of DNA replication with histone
gene transcription. Indeed, subsets of Cajal bodies had previously been
found to physically associate with histone gene clusters onTable 5
Top gene pathways reversed in the induced model by administration of the therapeutic
ASO.
Ingenuity canonical pathways − log(P)
Cell cycle signaling 6.19
Granulocyte adhesion and diapedesis 3.59
Inhibition of angiogenesis by TSP1 3.17
Interferon signaling 3.17
Cell cycle: G2/M DNA damage checkpoint regulation 2.84
Role of pattern recognition receptors in recognition of
bacteria and viruses
2.84
Pancreatic adenocarcinoma signaling 2.67
Agranulocyte adhesion and diapedesis 2.60
PI3K/AKT signaling 2.45
Activation of IRF by cytosolic pattern recognition receptors 2.40
Cell cycle: G1/S checkpoint regulation 2.34
Hepatic ﬁbrosis/hepatic stellate cell activation 2.26
Molecular mechanisms of cancer 2.10
Role of p14/p19ARF in tumor suppression 2.00
Proline degradation 2.00
Chronic myeloid leukemia signaling 1.92
Thyroid cancer signaling 1.76
Melanoma signaling 1.72
Role of RIG-1-like receptors in antiviral innate immunity 1.68
ASO, antisense oligonucleotide; IRF, interferon regulatory factor; TSP-1, thrombospondin-1.chromosomes 1 and 6 [26], one component of which, Hist1H1C, was
among the earliest transcripts we found to be dysregulated in the in-
duced SMAmodel. Our data also showed robust activation of transcripts
associated with p53-mediated cell cycle arrest, including Cdkn1a (p21),
Ccng1 (cyclin G1), andGtse1 (G2 and S phase-expressed protein 1), sug-
gesting that some form of DNA damage is proximal to SMN depletion.
Evidence for perinatal DNA damage in a mouse model of severe SMA
is consistent with this possibility [27].
SMN itself is recruited, through its N-terminal Tudor domain, to di-
methylated histone H3K79 in the setting of the interphase centromere
damage response [28]. Whether SMN is involved in executing this re-
sponse or other forms of DNA repair, such as double-strand break repair,
known to be mediated by another Tudor-domain protein, 53BP1, in an
H3K79me-dependentmanner [29], is a question thatwarrants further in-
vestigation. Of note, SMNhas been shown to interact physically and func-
tionally with FUS [20], an RNA- and DNA-binding protein that mediates
double-strand break repair through a histone deacetylase-1-dependent
mechanism [30]. SMN–gemin complexes and FUS associate within
gems, nuclear depots of snRNPs that serve asmarkers of SMNabundance,
and SMN overexpression overcomes the gem deﬁcit of FUS mutant lines
from patients with amyotrophic lateral sclerosis [20]. Whether gems or
the closely associated Cajal bodies couple their roles in splicing and tran-
scription with the DNA damage response is unknown. Although we can-
not rule out the contribution of reactive glial proliferation to cell cycle
expression changes in the SMA model, a recent study showed that puri-
ﬁedmotor neuron precursors derived frommouse SMA embryonic stem
cells (ESCs) also showmarked up-regulation of cell proliferation genes or
proteins, including p21, encoded by Cdkn1a [21]. Curiously, p21 levels are
up-regulated over 40-fold in SMA mESCs compared to control mESCs,
whereas Cdkn1amRNA levels are down-regulated 0.76-fold [21]. Togeth-
er, these data suggest that post-transcriptional and post-translational
regulation of certain mRNAs and proteins disrupted in SMAmay depend
on the cell cycle status of the cells studied (e.g. proliferating mESC-
derived motor neuron precursors versus post-mitotic motor neurons
of the spinal cord).
Determining deﬁnitively whether the global expression changes ob-
served in this study are primary or secondary to SMN status will require
further investigation, but our data clearly support the utility of induced
models of severe disease, whereby the proximal consequences of gene
depletion can be more cleanly dissociated from the more distal effects
of tissue pathology. Together with post-induction rescue, this study
highlights potential biomarkers and pathways of SMA progression and
therapeutic response. As clinical trials for SMA progress, it will be im-
portant to assess whether these expression changes are translatable to
the human disease and extend to other tissues or bioﬂuids more
accessible than spinal cord.
4. Material and methods
4.1. Oligonucleotides
Synthesis and puriﬁcation of all chemically modiﬁed oligonucleo-
tides were performed as previously described [31]. Therapeutic ASO,
5′-ATTCACTTTCATAATGCTGG-3′; skip ASO, 5′-GTGAGCACCTTCCTTC
TT-3′; and control ASO, 5′-CTCAGTAACATTGACACCAC-3′. ASOs are uni-
formly modiﬁed with 2′-O-methoxyethyl nucleotides and have a phos-
phorothioate backbone.
4.2. Dosing of mice
All protocols met ethical standards for animal experimentation and
were approved by the Institutional Animal Care and Use Committee.
Adult male and female mice with type III SMA (Smn–/–; SMN2+/+)
were obtained from the Jackson Laboratory (FVB.Cg-Tg(SMN2)2Hung
Smn1tm1Hung/J, stock number 005058). The lyophilized ASOs were dis-
solved in sterile phosphate-buffered saline (PBS) without calcium or
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then diluted to the desired concentration required for dosing mice and
sterilized through a 0.2 μm ﬁlter. ICV bolus injections were performed
as previously described [13].
4.3. RT-PCR for SMN2 analysis
For the spinal cord, a 2 mm lumbar section was collected. For the
brain, a 1 mm coronal section, 2 mm posterior to the injection site,
was collected. Each piece of tissue was homogenized in a 2ml tube con-
taining Lysing Matrix D (MP Biomedicals, LLC), 500 μl Buffer RLT
(QIAGEN) and 1% volume to volume ratio β-mercaptoethanol. Homog-
enization was performed for 20 s at 6000 rpm using a FastPrep Auto-
mated Homogenizer (MP Biomedicals, LLC). Lysate (10 μl) was used to
isolate RNA with an RNeasy 96 Kit (QIAGEN) that included in-column
DNA digestion with 50 U of DNase I (Invitrogen™). Real-time RT-PCR
was performed as previously described [32], except that full-length
SMN2 transcripts were analyzed with primers 5′-GCTGATGCTTTGGG
AAGTATGTTA-3′ and 5′-TTTGATTTTGTCTAAAACCCATATA-3′ and
probe 5′FAM/TACATGAGTGGCTATCATACT/3′MGBNFQ. The full-length
or Δ7 SMN2 expression level was normalized to that of total SMN2,
and this was further normalized to the level in PBS-treated mice.
4.4. Immunostaining and immunoblotting
Staining of SMN protein in mouse tissues was performed as pre-
viously described [10]. Protein from spinal cord tissue was extracted
with RIPA buffer with protease and phosphatase inhibitors, run on
4%–12% Bis-Tris gels (Novex), and probed with the following
antibodies: anti-SMN (BD 6106-46, 1:1000); anti-Gemin 2 (Abcam
ab6084[2E17]; 1:500); anti-Gemin 8 (Santa Cruz 130669; 1:500);
anti-Igfbp2 (R&D Systems AF797 0.2 μg/ml); anti-Eda2r (Abnova
H0060401-D01P, 1:500); anti-Sgca (Origene TA314526, 1:1000);
and anti-p21 (Cell Signaling cs2947, 1:1000).
4.5. Microarray proﬁling
4.5.1. RNA preparation
Snap-frozen mouse spinal cord or brain tissue was homogenized in
QIAzol Lysis Reagent (QIAGEN) and processed to RNA according to the
manufacturer's recommendation. Puriﬁed RNA was further cleaned
using the RNeasy Mini Kit (QIAGEN) with on-column DNase treatment
as speciﬁed by the manufacturer. RNA integrity was assessed using
LabChip GX (PerkinElmer, Inc.); quantities and 260/280 ratios were
assessed using DropSense96 (PerkinElmer, Inc.). RNA samples with an
RNA quality score N7.5 were considered high quality and were used
for downstream genomic applications.
4.5.2. Sample preparation for exon and 3′ arrays
Samples were prepared for exon arrays using 100 ng of total RNA.
RNA was manually ampliﬁed and the resulting sense cDNA was
fragmented and labeled using the using Ambion® WT Expression Kit
for high-throughput robotics (Life Technologies Corporation) according
to themanufacturer's recommendations. For 3′ arrays, automated sam-
ple ampliﬁcations and biotin labelings were carried out using 50 ng of
total RNA with the Ovation RNA Ampliﬁcation System V2, Ovation®
Whole Blood Solution and Encore® Biotin Module (NuGEN Technolo-
gies, Inc.) according to the manufacturer's recommendations using a
Biomek FxP automated liquid handler (Beckman Coulter).
4.5.3. Hybridization, washing, scanning and image generation
Ambion or NuGEN fragmented and labeled cDNA was hybridized
overnight to GeneChip® Mouse Gene 1.1 ST or GeneChip® HT MG-
430PM plate arrays for exon array analysis or 3′ analysis, respectively
(Affymetrix, Inc.). Plate arrays were washed and stained on a
GeneChip® Array Station automated liquid handler (Caliper LifeSciences) according to the manufacturer's recommendations. Plate ar-
rays were then scanned and array images (.dat ﬁles) were generated
using aGeneTitan®HTplate scanner (Affymetrix, Inc.). Probe cell inten-
sity (.cel) and global quality metric (.rpt) ﬁles for each scanned image
were generated and imported into Spotﬁre (TIBCO Spotﬁre) for visuali-
zation and comparison with the historical data from the same type of
arrays.
4.5.4. Data analysis
Gene-expression analysis for the 3′ array was performed using R/
Bioconductor (R version 2.11.1; Bioconductor), while exon arrays
were analyzed using Partek® Genomics Suite™ (Partek GS; version
6.5; Partek Inc.). Probe sets mapped to the same transcript cluster
were grouped together, and Guanine Cytosine RobustMulti-Array Anal-
ysis method was used for normalization. Differential gene-expression
was measured by empirical Bayes t-statistics and P-values were adjust-
ed for false discovery rate (FDR) correction. Selected genes with (1) a
FDR-adjusted P-value ≤ 0.05 using the Benjamini–Hochberg multiple
testing procedure [33] and (2) an absolute fold change difference be-
tween groups ≥1.5-fold were analyzed for high-throughput qPCR vali-
dation as described below.
The quality assurance, data normalization, principal component
analysis, multiple dimensional scaling and reduction, box plots, dot
plots and volcano plots for exon arrays were performed by Partek GS.
Genes with alternative splicing were analyzed using the Partek GS
mixed analysis of variance model. Errors from multiple exons within
the same transcript cluster were assumed to be independent. Such con-
ditional independence allows one to derive a joint multivariate normal
distribution so that relevant parameters and their standard errors can
be estimated. We invoked the ALT-SPLICE ANOVA option under the
STAT menu per the Partek GS manual. P-values and F-statistics on the
exon and group interactions were extracted from Partek GS outputs.
4.6. High-throughput qPCR validation
4.6.1. Primer probe design
TaqMan®MGB probes and primer sets were designed to exon junc-
tions orwithin single exons using Primer Express®Software Version 3.0
(Life Technologies Corporation) using default settings.
4.6.2. cDNA synthesis, sample and assay preparation
RNA (200 ng) was treated with DNAse using DNase I, Ampliﬁcation
Grade (Invitrogen™) and reverse transcribed using the HighCapacity
cDNAReverse Transcription Kit (Life Technologies Corporation) accord-
ing to the manufacturer's recommendations. The reverse transcribed
cDNAwas pre-ampliﬁed with pooled assays and the TaqMan® PreAmp
Master Mix (2×; Life Technologies Corporation) according to the
manufacturer's recommendations. Pre-ampliﬁed cDNA samples were
prepared for loading into a 96 × 96 array by diluting 5-fold and mixing
with 2× TaqMan® Gene Expression Master Mix (Life Technologies
Corporation) and 20× gene-expression sample loading reagent.
TaqMan 20× assays were pooled and mixed with 2× assay loading re-
agent to a ﬁnal concentration of primers 9 μM and probe 2 μM in the
10× assay mix.
4.6.3. Array priming, loading, thermocycling and data collection
Dynamic arrays (96 × 96) from Fluidigm Corporation were primed
using the Prime (136×) script in an integrated ﬂuidic circuit controller
HX according to the manufacturer's recommendations. Aliquots of
5 μL of 10× assay mix or prepared cDNA samples were added into a
96 × 96 dynamic array and loaded into the chip using the Load Mix
(136×) script in an integrated ﬂuidic circuit controller HX according
to the manufacturer's recommendations. The loaded 96 × 96 arrays
were then thermal mixed: 50 °C, 120 s; 70 °C, 1800 s; 25 °C, 600 s;
followed by UNG and Hot Start: 50 °C, 120 s and 95 °C, 600 s; and
thermocycled: 95 °C, 15 s; 60 °C, 60 s, for 40 cycles on the BioMark™
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derivative for baseline correction, quality threshold set to 0.65 and auto-
matic Ct thresholds.
4.6.4. Analysis
Fluidigm data were quality controlled and normalized based on the
expression levels of the housekeeping genes. Afterﬁltering out the qual-
ity control failures, datawere normalized using theΔΔmethod [34]. The
Ct values of the samples of interest were compared with universal
human control values as the calibrator. The Ct values of both the calibra-
tor and the samples of interest were normalized to an appropriate en-
dogenous housekeeping gene. The normalized ΔΔ Ct values were
analyzed in JMP 9.0.3 (SAS Institute Inc.) to evaluate any signiﬁcant
changes (FDR-adjusted P-value b 0.05) in gene expression.
4.7. Gene ontology and pathway analysis
Transcripts/genes from the above differential analysis were subject-
ed to the enrichment test for gene ontology and pathway analysis using
the Ingenuity Pathway Analysis tool (QIAGEN). Lists of the most
enriched pathways and their P-values based on Fisher's exact test are
presented.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2015.01.007.
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